Producer
Cytiva (formerly GE Healthcare Life Sciences)
World's largest single-use bioreactor bag manufacturer; ~40–45% global market share. Spun out from GE Healthcare and acquired by Danaher Corporation in 2020 ($21.4B). Revenue ~$4B (2024). Produces WAVE Cellbag™ bioreactor bags (10 mL to 1,000 L) used in mAb, vaccine, and cell therapy production. Cytiva's Cellbag was the primary bottleneck limiting COVID-19 vaccine production speed in 2020–21. Manufacturing at Logan, UT (US), Umeå (Sweden), and Whatman, Maidstone (UK).
2
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
2 inputs Cytiva (formerly GE Healthcare Life Sciences) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Cytiva (formerly GE Healthcare Life Sciences) makes, pick one to see the full supply chain.
Where they make it
2 facilities
Cytiva Logan (Utah) Bioreactor Bag Plant →
USLogan, Utah · manufacturing
Primary Cytiva US bioreactor bag manufacturing facility. Produces WAVE Cellbag and Xcellerex single-use bags. During COVID-19 (2020–21), this facility operated 24/7 with a 12–18 month backlog for bags needed for mRNA vaccine production. The polyethylene film used here must meet USP Class VI / ISO 10993 biocompatibility standards — a small number of film suppliers qualify.
Cytiva Umeå Bioreactor Bag Plant (Sweden) →
SEUmeå, Sweden · manufacturing
Cytiva European bioreactor bag manufacturing in Sweden. Serves European biopharma customers (Novartis, Roche, AstraZeneca). Together with Logan UT, these two plants produce the majority of global Cellbag supply. Swedish facility also produces Sephadex and Sepharose chromatography resin.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Single-Use Bioprocessing (WAVE/Xcellerex)
35%Chromatography (Resin & Systems)
30%Cell Therapy & Gene Therapy
15%Filtration & Analytical
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Cytiva's single-use bioreactor bags (WAVE Cellbag) are used for commercial monoclonal antibody manufacturing (Humira, Keytruda production), COVID mRNA vaccine manufacturing, US government biodefense vaccine stockpiling (BARDA contracts), and CAR-T cell therapy manufacturing. All four applications use the same proprietary EVA-based multilayer film bioreactor bag from Cytiva's Logan, Utah facility. During COVID-19, Cytiva's Cellbag production was the rate-limiting step in global vaccine manufacturing speed -- WHO, Gavi, and national governments tried to boost vaccine production in 2020-2021 and found that Cytiva could not supply enough bags. A Danaher subsidiary's Utah bag factory determined vaccine rollout timelines globally. The same bags that produce the cancer immunotherapy treating a patient in Houston also produce the pandemic vaccines stockpiled by the US military for biodefense.
Cytiva (Danaher) ↗Origin2023
Cytiva was created from GE Healthcare's 2004 acquisition of Amersham Biosciences -- a company that had grown from Amersham International, a UK government-created organization established in 1946 to commercialize radioisotope byproducts from the UK's nuclear weapons program. Amersham (named after the Buckinghamshire town near Harwell nuclear research center) handled radioactive material for nuclear medicine and eventually diversified into life science tools as nuclear medicine demand flattened. GE acquired Amersham to build a life sciences instrumentation platform alongside its medical imaging business. In 2020, Danaher acquired GE Healthcare Life Sciences for $21.4B, rebranding it Cytiva. The lineage runs: UK nuclear weapons program byproducts (1946) → nuclear medicine radiotracer company → life science tools → global bioreactor bag monopoly for COVID vaccine production. The single-use bag that limits mRNA vaccine manufacturing capacity has its corporate origin in UK nuclear weapons infrastructure.
Cytiva (Danaher) ↗Incident2020
Cytiva was created when Danaher Corporation bought GE Healthcare Life Sciences in 2020 for $21.4B — completing the deal at the exact moment COVID-19 began accelerating global vaccine demand. Cytiva immediately became the most strategically critical pharmaceutical equipment supplier in the world: its WAVE Cellbag and Äkta chromatography systems were the limiting reagents for COVID vaccine production. Danaher's stock performance during 2020–22 was significantly driven by Cytiva's vaccine supply position.
Danaher Corporation ↗